What Is Hereditary Angioedema and How Is It Treated?

Hereditary angioedema is a rare genetic condition that causes repeated episodes of severe swelling beneath the skin and in the lining of the gut and airway. Unlike common allergic swelling, it stems from a defect in a single regulatory protein and does not respond to antihistamines, epinephrine, or steroids. Left unrecognized, airway attacks can be fatal, yet the average person with the condition waits more than a decade before receiving the correct diagnosis. The science behind why attacks happen and how they can now be prevented has advanced dramatically, but awareness still lags far behind the available treatments.

What Goes Wrong in the Body

The protein at the center of hereditary angioedema is called C1 inhibitor, often shortened to C1-INH. It acts as a brake on two powerful cascading systems in the blood: the complement system, which helps fight infection, and the contact system, which is involved in blood clotting and inflammation.¹ When C1-INH is missing or does not work properly, the contact system runs unchecked, and the end result is overproduction of a small molecule called bradykinin.

Bradykinin is the direct troublemaker. It latches onto receptors on the walls of tiny blood vessels and forces them to leak fluid into surrounding tissues. That fluid buildup is the swelling people with hereditary angioedema experience. Research in both human patients and animal models has confirmed that bradykinin, not complement activation as was once assumed, is the primary driver of attacks. During active episodes, bradykinin can be detected at elevated levels in the bloodstream, and drugs that block bradykinin or its production resolve attacks while complement-targeted treatments do not.²

How It Is Inherited

Hereditary angioedema follows an autosomal dominant inheritance pattern, meaning a child needs only one copy of the faulty gene from one parent to develop the condition. The gene responsible in the vast majority of cases is SERPING1, which provides the instructions for making C1-INH. Mutations in SERPING1 account for more than 95% of all hereditary angioedema cases.³ The gene sits on chromosome 11 and is remarkably variable: roughly 450 different mutations have been catalogued.⁴

Two main subtypes arise from SERPING1 mutations. In type 1, the body simply does not produce enough C1-INH protein. In type 2, it produces normal amounts of the protein but the protein itself is dysfunctional.⁵ Both types produce the same clinical picture because the end result is the same: insufficient regulation of bradykinin.

About a quarter of people diagnosed with C1-INH-related hereditary angioedema have no family history of the disease. Their mutations arose spontaneously rather than being passed down from a parent.⁶ This is an important point for diagnosis: the absence of affected relatives does not rule it out.

Hereditary Angioedema with Normal C1-INH

A smaller and more recently recognized category of the disease involves people who have perfectly normal C1-INH levels and function, yet still experience the same pattern of recurrent bradykinin-driven swelling. In some of these families, researchers have traced the problem to mutations in the gene for coagulation factor XII (the Hageman factor).⁷ Two specific missense mutations at the same position within exon 9 of the F12 gene have been identified across multiple unrelated families.⁸

This form of the disease is clinically similar, with skin swelling, abdominal pain attacks, and the risk of airway obstruction.⁹ It presents a diagnostic challenge because the usual blood tests for C1-INH come back normal. Genetic testing is the only reliable way to confirm it.

What Attacks Look and Feel Like

Swelling episodes tend to hit three main areas, sometimes one at a time, sometimes in combination:

Skin: Deep, non-itchy swelling of the hands, feet, face, or genitals. Unlike hives, the swelling sits below the skin surface and is not red or bumpy.
Abdomen: Swelling of the intestinal wall can cause intense cramping, nausea, vomiting, and diarrhea. Imaging may show thickened bowel walls and fluid in the abdomen.¹⁰
Airway: Swelling of the tongue, throat, or larynx. This is the most dangerous presentation: undiagnosed or poorly managed airway attacks carry a mortality rate estimated between 30 and 50 percent.¹¹

A critical distinguishing feature is the absence of hives. Allergic angioedema almost always comes with itchy welts on the skin, while bradykinin-mediated swelling does not.¹² This single clinical clue, no hives alongside recurring swelling, should prompt a doctor to consider hereditary angioedema.

Episodes typically develop over hours, peak within a day or two, and then slowly resolve over two to five days without treatment. They are unpredictable and can strike at any time, though certain triggers increase the risk.

Common Triggers

Physical trauma, even minor procedures like dental work, is one of the best-documented triggers. An observational study of dental procedures found that patients who underwent tooth extractions without preventive treatment were at risk for post-procedural attacks, including laryngeal swelling.¹³ Emotional stress, infections, and hormonal fluctuations also play a role. In women, elevated estrogen states are a particularly well-known trigger. Pregnancy and oral contraceptive use can provoke or worsen attacks, and some women with the factor XII form of the disease only experience symptoms during high-estrogen periods.¹⁴ A class of blood pressure medications called ACE inhibitors is also a known precipitant, because those drugs slow the breakdown of bradykinin, which is already overproduced in these patients.

Why Diagnosis Takes So Long

One of the most frustrating aspects of hereditary angioedema is the diagnostic delay. A Germany-wide survey found a mean delay from first symptoms to correct diagnosis of about 18 years, with a median of 15 years. Half of the patients surveyed had been misdiagnosed at least once, most commonly with appendicitis or allergy. Among those who were misdiagnosed, 80% received inappropriate treatment, including unnecessary surgeries in over half the cases.¹⁵ A separate analysis found that patients who had received a prior misdiagnosis waited a median of about 13 years for the correct one, compared with under 2 years for patients who had not been mislabeled.¹⁶

The reason for these delays is partly structural: the disease is rare, abdominal attacks look like surgical emergencies, and skin swelling without hives does not fit the mental model most doctors have for angioedema. Standard allergy workups come back negative because the mechanism is entirely different. Once a clinician suspects hereditary angioedema, however, confirmation is straightforward. A blood test measuring C4 complement levels (which are chronically low in C1-INH deficiency) along with C1-INH protein levels and functional activity can establish the diagnosis in most cases.¹⁷ Awareness, not laboratory capability, remains the bottleneck.

Treating an Acute Attack

Because hereditary angioedema does not respond to the usual emergency toolkit of epinephrine, antihistamines, and corticosteroids, targeted therapies are essential.¹⁸ Three classes of drugs can stop an attack once it starts:

C1-INH concentrates: These replace the missing protein directly. At the right dose, relief can begin within about 30 minutes, and the benefit is most dramatic for severe attacks.¹⁹ A nanofiltered version also showed onset of relief in about 2 hours compared with over 4 hours for placebo, and when used as regular prophylaxis, it roughly halved the number of attacks.²⁰
Icatibant: A bradykinin receptor blocker that patients can inject themselves at home. In a pivotal trial, the median time to significant symptom reduction was 2 hours with icatibant versus nearly 20 hours with placebo for skin and abdominal attacks.²¹ Self-administration data showed median first improvement within about 15 minutes for type 1 attacks.²²
Ecallantide: A plasma kallikrein inhibitor that blocks bradykinin production upstream. It must be given by a healthcare provider because of a small risk of severe allergic reactions.

The ability for patients to self-administer treatment at home has been transformative. Early treatment shortens attacks and prevents progression to airway involvement. Emergency departments still play a role when laryngeal swelling threatens the airway, and in extreme cases, emergency tracheotomy may be required to secure breathing.²³

Preventing Attacks Before They Start

For people with frequent or severe episodes, long-term preventive therapy can dramatically reduce the burden of disease. Two newer options have reshaped the landscape:

Lanadelumab is an injectable monoclonal antibody that targets plasma kallikrein. In a randomized trial, patients receiving the most effective dose (every two weeks) averaged about one attack every four months, compared with roughly two per month on placebo.²⁴ In an open-label extension study, the overall attack rate dropped by about 87% from baseline, and roughly 69% of patients went at least 12 months without a single attack. Patients were attack-free for an average of about 98% of their days on treatment.²⁵

Berotralstat is the first oral preventive therapy, taken as a daily pill. In a large phase 3 trial, the 150 mg dose reduced attacks to about 1.3 per month versus about 2.4 per month on placebo.²⁶ Long-term data showed attack rates continued to fall over time, reaching a median of zero attacks per month by the end of a year, with no sign of the drug losing effectiveness.²⁷ The most common side effects were gastrointestinal: abdominal pain, diarrhea, and occasional vomiting, generally mild to moderate.²⁸

Short-term prophylaxis is also important. Before dental work, surgery, or other procedures that involve physical trauma to the mouth or airway, a dose of C1-INH concentrate given beforehand can prevent a procedure-triggered episode.²⁹

Gene Editing as a Potential Cure

The most exciting frontier in hereditary angioedema treatment does not aim to replace a missing protein or block a receptor. It aims to rewrite the problem at the genetic level. Lonvoguran ziclumeran (NTLA-2002) is the first CRISPR-Cas9 gene-editing therapy designed to be given as a single intravenous infusion and provide lasting disease control. Rather than fixing the broken SERPING1 gene directly, it targets KLKB1, the gene that encodes the precursor to plasma kallikrein. By permanently disrupting that gene, the therapy cuts off the enzyme that generates bradykinin in the first place.³⁰

Early clinical results have been published in a major medical journal, with the goal of demonstrating lifelong attack control from a single dose.³¹ If the approach holds up in larger and longer trials, it could shift hereditary angioedema from a lifelong condition requiring ongoing treatment to one that is effectively cured with a single intervention. Larger phase 3 data are still needed, and the long-term safety profile of in-vivo CRISPR editing in humans is still being established, but the concept is genuinely novel: this is one of the first systemic gene-editing therapies applied to any disease in living patients.

Living with Hereditary Angioedema

Beyond the physical danger and discomfort, the psychosocial toll of hereditary angioedema is substantial. A multinational patient survey found that about 38% of patients reported moderate to severe anxiety and 17% reported moderate to severe depression. Higher attack frequency was associated with worse quality of life and greater impairment in daily activities and work productivity.³² A Canadian cohort study found similarly high rates of depression and anxiety, along with an average impairment of about 20% in daily activities outside of work.³³

The unpredictability of attacks feeds much of this anxiety. People may avoid travel, social events, or physical activity out of fear that an episode could begin far from treatment. Facial swelling can cause embarrassment and social withdrawal. Abdominal attacks mimic food poisoning or surgical emergencies, leading to repeated ER visits and, in undiagnosed patients, unnecessary operations. Effective long-term prophylaxis has been shown to improve not just attack frequency but also quality-of-life scores, suggesting that reducing unpredictability is as valuable as reducing swelling itself.

Children and Adolescents

Hereditary angioedema often begins in childhood, and early onset may predict a more severe course later in life. Diagnosis in children carries its own difficulties: abdominal pain is common in the general pediatric population, so recurrent belly aches may not immediately raise suspicion. International consensus guidelines recommend that all newborns born to an affected parent be screened for C1-INH deficiency, though because C1-INH levels can be naturally lower in infants under one year of age, a confirmatory test after the first birthday is advised.³⁴

Treatment options for children are more limited than for adults, with only a few agents licensed specifically for pediatric use. Plasma-derived C1-INH concentrates are the mainstay for acute treatment in younger patients.³⁵ Managing the condition in adolescents adds another layer of complexity, since hormonal changes during puberty can alter attack patterns, and teenagers face unique challenges around treatment adherence and the social impact of a visible chronic illness.

Pregnancy and Hormonal Considerations

Pregnancy is a particularly delicate period for women with hereditary angioedema. Hormonal shifts can either worsen or, less commonly, improve attack frequency, and the effect is unpredictable from one pregnancy to the next. Several of the drugs used for long-term prevention, including androgens like danazol, are contraindicated during pregnancy because of the risk of harm to the developing fetus. Plasma-derived C1-INH concentrate is generally considered the safest option for both acute treatment and short-term prophylaxis during pregnancy and around delivery.³⁶ Estrogen-containing contraceptives are typically avoided because of their potential to trigger or worsen attacks, making contraceptive choices more limited for women with the condition.³⁷

Planning ahead is essential. Women with known hereditary angioedema benefit from working with both their immunologist and their obstetrician before conception, so that a treatment plan is in place for each stage of pregnancy, labor, and the postpartum period. Breastfeeding considerations also factor in, as the safety data for newer therapies during lactation are still accumulating.

1
PubMed. C1 inhibitor, a multi-functional serine protease inhibitor ↩︎
2
Clinical Immunology. The pathophysiology of hereditary angioedema ↩︎
3
Genes & Diseases. An update on the genetics and pathogenesis of hereditary angioedema ↩︎
4
Genes & Diseases. An update on the genetics and pathogenesis of hereditary angioedema ↩︎
5
PubMed. Hereditary angioedema: Historical aspects, classification, pathophysiology, clinical presentation, and laboratory diagnosis ↩︎
6
Genes & Diseases. An update on the genetics and pathogenesis of hereditary angioedema ↩︎
7
PubMed Central. Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor ↩︎
8
PubMed. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor ↩︎
9
PubMed. Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII) ↩︎
10
PubMed Central. Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency ↩︎
11
PubMed Central. Management of upper airway edema caused by hereditary angioedema ↩︎
12
PubMed. Recognition and Differential Diagnosis of Hereditary Angioedema in the Emergency Department ↩︎
13
PLoS ONE. Short-term prophylaxis in patients with angioedema due to C1-inhibitor deficiency undergoing dental procedures: An observational study ↩︎
14
PubMed. High Estrogen States in Hereditary Angioedema: a Spectrum ↩︎
15
PubMed Central. A Germany-wide survey study on the patient journey of patients with hereditary angioedema ↩︎
16
PubMed. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting ↩︎
17
PubMed Central. Diagnosis and screening of patients with hereditary angioedema in primary care ↩︎
18
PubMed. Recognition and Differential Diagnosis of Hereditary Angioedema in the Emergency Department ↩︎
19
PubMed. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks ↩︎
20
PubMed. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema ↩︎
21
Annals of Allergy, Asthma & Immunology. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial ↩︎
22
PubMed Central. Safety and efficacy of icatibant self-administration for acute hereditary angioedema ↩︎
23
PubMed. Hereditary angioedema-induced laryngeal edema: A diagnostic and therapeutic race against time ↩︎
24
JAMA. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial ↩︎
25
PubMed Central. Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study ↩︎
26
PubMed. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial ↩︎
27
PubMed Central. Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study ↩︎
28
PubMed Central. Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study ↩︎
29
PLoS ONE. Short-term prophylaxis in patients with angioedema due to C1-inhibitor deficiency undergoing dental procedures: An observational study ↩︎
30
PubMed. Lonvoguran ziclumeran: a CRISPR-CAS9-based gene therapy for the treatment of hereditary angioedema ↩︎
31
PubMed. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema ↩︎
32
PubMed Central. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey ↩︎
33
PubMed Central. Psychosocial burden of type 1 and 2 hereditary angioedema: a single-center Canadian cohort study ↩︎
34
PubMed Central. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency ↩︎
35
PubMed Central. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency ↩︎
36
PubMed Central. Management of hereditary angioedema in pregnant women: a review ↩︎
37
PubMed. High Estrogen States in Hereditary Angioedema: a Spectrum ↩︎